Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: A comparative study.
AIMS
Post-renal-transplanted patients frequently present hyperglycemia immediately after the procedure. The goal of this work was to evaluate the effect of linagliptin + insulin in post-renal-transplanted patients with hyperglycemia.


METHODS
Retrospective comparative study in post-renal transplanted patients with hyperglycemia after transplantation who were treated with linagliptin 5 mg daily plus insulin vs insulin alone for 5 days after renal transplantation with hyperglycemia. Main outcomes were glucose levels, insulin dose and severity of hypoglycemia.


RESULTS
There were 14 patients treated with linagliptin + insulin and 14 patients treated only with insulin. Glucose levels and insulin doses were lower in the linagliptin + insulin group in comparison with the insulin alone group, 131.0 ± 15.1 vs 191.1 ± 22.5 mg/dl (7.27 ± 0.84 vs 10.61 ± 1.25 mmol/l) and 37.5 ± 6.3 vs 24.2 ± 6.6 U, respectively (p < 0.05). Hypoglycemia was less severe in the linagliptin + insulin group, 65.1 ± 2.2 vs 54.2 ± 3.3 mg/dl (3.61 ± 0.12 vs 3.00 ± 3.3 ± 0.18 mmol/l), p 0.036.


CONCLUSIONS
The combination of linagliptin + insulin provided better glycemic control with a lower insulin dose and less severe hypoglycemia in comparison to insulin alone in patients with hyperglycemia immediately after renal transplantation.
['Guardado-Mendoza|Rodolfo|R|', 'Cázares-Sánchez|David|D|', 'Evia-Viscarra|María Lola|ML|', 'Jiménez-Ceja|Lilia M|LM|', 'Durán-Pérez|Edgar G|EG|', 'Aguilar-García|Alberto|A|']
D004359:Drug Therapy, Combination D005260:Female D006801:Humans D006943:Hyperglycemia D007004:Hypoglycemic Agents D007328:Insulin D016030:Kidney Transplantation D000069476:Linagliptin D008297:Male D008875:Middle Aged D012189:Retrospective Studies
Linagliptin Hyperglycemia Renal transplantation